Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 9/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | EP300 | Q09472 | 4/20 | 0.34 |
| ▸ | ACP1 | P24666 | 3/20 | 0.34 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5649416 | 0.92 | MEN1 (0.37) | PTPN1OPRL1MEN1CYP3A4CYP2D6 | |
| SCHEMBL5648860 | 0.91 | PTPN1 (0.35) | PTPN1KMT2AEP300ACP1PTPN2 | |
| SCHEMBL5648344 | 0.90 | KMT2A (0.35) | PTPN1MEN1KMT2AEP300ACP1 | |
| SCHEMBL5647692 | 0.86 | PTPN1 (0.36) | PTPN1KMT2AEP300ACP1PTPN2 | |
| SCHEMBL5648937 | 0.85 | KMT2A (0.36) | PTPN1MEN1KMT2AEP300ACP1 | |
| SCHEMBL5645636 | 0.84 | F10 (0.38) | OPRL1HDAC6 | |
| SCHEMBL6098666 | 0.82 | OPRL1 (0.35) | PTPN1OPRL1MEN1CYP3A4CYP2D6 | |
| SCHEMBL5650375 | 0.82 | OPRL1 (0.35) | PTPN1OPRL1MEN1CYP3A4CYP2D6 | |
| SCHEMBL5647778 | 0.82 | PTPN1 (0.46) | PTPN1OPRL1MEN1CYP3A4CYP2D6 | |
| SCHEMBL5650040 | 0.79 | PTPN1 (0.45) | PTPN1MEN1KMT2AACP1PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199146-B2 | Imidazolidinedione analogs useful as anticoagulants and antithrombotics | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-04-03 | — | — | US | disclosed |
| US-20060142363-A1 | Imidazolidinedione analogs useful as anticoagulants and antithrombotics | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-29 | — | — | US | disclosed |
| US-7053112-B2 | Imidazolidinedione analogs useful as anticoagulants and antithrombotics | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-05-30 | — | — | US | disclosed |
| US-20040122073-A1 | Imidazolidinedione analogs useful as anticoagulants and antihrombotics | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122073-A1 | Imidazolidinedione analogs useful as anticoagulants and antihrombotics | SERPINC1, F2, BDKRB1 | PTPN1 1843/4885OPRL1 3903/4885MEN1 795/4885 |
| US-20060142363-A1 | Imidazolidinedione analogs useful as anticoagulants and antithrombotics | SERPINC1, F2, BDKRB1 | PTPN1 1936/4885OPRL1 4078/4885MEN1 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.